NSE · ALPA
Alpa Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹24 Cr with net profit ₹1 Cr — a 4.35% net margin, versus 4.33% the period before.
Shareholding
As of 2026-06-30
- Promoter57.19%
- Public42.39%
- FII0.35%
- DII0.07%
17,643 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.06× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #71 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,43,013 Cr | 35.06 | 5.29 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,15,940 Cr | 23.74 | 4.28 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,11,816 Cr | 31.24 | 3.24 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,08,414 Cr | 99.14 | 20.44 | 16.77% | 15.04% |
| Mankind Pharma Limited | ₹1,02,435 Cr | 48.02 | 6.28 | 11.74% | 13.86% |
| Dr Reddys Laboratories Ltd. | ₹1,01,080 Cr | 31.37 | 2.66 | 11.07% | 9.73% |
| Aurobindo Pharma Ltd. | ₹97,814 Cr | 25.87 | 2.58 | 9.25% | 10.7% |
| Lupin Limited | ₹97,631 Cr | 16.39 | 4.32 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹69,467 Cr | 22.26 | 6.61 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹63,746 Cr | 27.98 | 4.62 | 16.66% | 14.31% |
| Alpa Laboratories Ltd.(this company) | ₹129 Cr | 31.79 | 0.69 | 8.06% | 3.67% |
AI analysis
AI-generated · google/gemini-2.5-flashAlpa Laboratories Ltd. has a market capitalization of Rs 144 Cr. The company reported revenue of Rs 135.8 Cr, with a profit margin of 14.03%. Its debt-to-equity ratio stands at 0.02. The promoter holding as of June 30, 2026, was 57.1898%.
Positives
- +The company's debt-to-equity ratio is low at 0.02.
- +The promoter holding of 57.1898% as of June 30, 2026, indicates a significant stake by the promoters.
- +There are no reported promoter share pledges.
- +The company has a positive profit margin of 14.03%.
Negatives
- −Revenue growth was 3.4% which is relatively low.
- −Quarterly net profit was negative in March 2025 at -Rs 2.12 Cr and in March 2025 at -Rs 1.95 Cr.
- −The dividend yield is 0%, indicating no dividend payouts.
- −No information on business activities is specified.
Financial performance
Alpa Laboratories Ltd. reported revenue of Rs 135.8 Cr, with a revenue growth of 3.4%. The company's profit margin stood at 14.03%. Earnings per share (EPS) for the latest period were Rs 7.13. Over the last four quarters (Mar 2025 to Mar 2026), quarterly revenues have ranged from Rs 19.11 Cr to Rs 31.4 Cr, and net profit has ranged from -Rs 1.95 Cr to Rs 11.78 Cr.
Profitability & returns
The company's return on equity (ROE) is 8.06%, while the return on capital employed (ROCE) is 8.981%. The diluted earnings per share (EPS) is Rs 7.13. The company's profit margin is 14.03% on a revenue of Rs 135.8 Cr.
Balance sheet
Alpa Laboratories Ltd. has a book value per share of Rs 88.53. The debt-to-equity ratio is 0.02, indicating a low level of debt relative to equity. The company has no reported promoter pledges.
Ownership & pledges
Public shareholding is 42.389%. There are no reported promoter share pledges.
Regulatory & surveillance
The company is not currently under any reported surveillance measures. The latest shareholding data is available for the period ending June 30, 2026. No details are available regarding the company's business activities.
Data as of — price: 2026-09-23 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.